การรักษาภาวะโลหิตจางในผู้ป่วยโรคไตเรื้อรัง

Erslev A. Humoral regulation of red cell production. Blood 1953; 8: 349-357.

Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83: 59-67.

Bachmann S, Le Hir M, Eckardt KU. Colocalization of erythropoietin mRNA ecto-5’-nucleotidase immunoreactivity in peritubular cells of rat cortex indicates that fibroblasts produce erythropoietin. J HistochemCytochem 1993; 41: 335-41.

Fried W. The liver as a source of extrarenal erythropoietin production.Blood 1972; 40: 671-7.

Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162: 1401-8.

Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am SocNephrol 2002; 13: 504-10.

Vecchio M, Palmer SC, Tonelli M, Johnson DW, Strippoli GF. Depression and sexual dysfunction in chronic kidney disease: a narrative review of the evidence in areas of significant unmet need. Nephrol Dial Transplant 2012; 27: 3420-8.

Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med 2012; 9(9): e1001307. Epub 2012 Sep 11.

Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006; 19: 161-7.

Babitt JL, Lin HY. Mechanisms of anemia in chronic kidney disease. J Am SocNephrol 2012; 23: 1631-4.

Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care 2008; 35: 329-vii. doi: 10.1016/j.pop.2008.01.008

Shander A, Sazama K. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. Transfusion 2010; 50: 1144-55. doi: 10.1111/j.1537-2995.2009.02551.x. Epub 2010 Jan 15.

Lankhorst CE, Wish JB. Anemia in renal disease: diagnosis and management. Blood Rev 2010; 24: 39-47. Epub 2009 Oct 14.

RDA modifies dosing recommendations for Erythropoiesis-Stimulating Agents. FDA NEWS RELEASE: June 24, 2011.

Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369(9559): 381-8. 19.

ศุภชัย ฐิติอาชากุล, อดิศว์ ทัศณรงค.์ การศึกษาผลของยา Erythropoietin ทางคลินิกระยะ 12 สัปดาห์ใน

ผู้ป่วยไตวายเรื้อรังที่ได้รับการฟอกเลือด. จดหมายเหตุทางการแพทย์ 2550; 90: 636-42.

Thanakitcharu P, Siriwiwatanakul N. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilarepoetin-alfa in hemodialysis patients with anemia. J Med Assoc Thai 2007; 90: 2574-86.

แนวทางเวชปฏิบัติสำหรับโรคไตเรื้อรังก่อนการบำบัดทดแทนทางไตสมาคมโรคไตแห่งประเทศไทย 2552.

Centers for Medicare and Medicaid Services, Kinney R. 2005 Annual Report: ESRD Clinical Performance Measures Project. Am J Kidney Dis 2006; 48 (4 suppl 2): S1-106.

Jeloka TK, Upase S, Chitikeshi S. Monthly cost of three exchanges a day peritoneal dialysis is same as of thrice a week hemodialysis in self-paying Indian patients. Indian J Nephrol 2012; 22: 39-41.

Pagé DE, House A. Important cost differences of blood transfusions and erythropoietin between hemodialysis and peritoneal dialysis patients. AdvPerit Dial 1998; 14: 87-9.

Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant humanerythropoietin in anemic patients with endstagerenal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000.

Engert A. Recombinant human eythropoietin as an alternative to blood transfusion in cancer-related anaemia. Disease Management and Health Outcomes 2000; 8: 259-272.

Di Iorio B, Guastaferro P, Bellizzi V. Relationship between resistance to erythropoietin and high anomalous hemoglobin levels in hemodialysis patients with beta-thalassemia minor. Blood Purif 2003; 21: 376-80.

Sanchaisuriya K, Fucharoen S, Fucharoen G, Ratanasiri S, Sanchaisuriya P, Changtrakul Y, et al. A reliable screening protocol for thalassemia and hemoglobinopathies in pregnancy: an alternative approach to electronic blood cell counting. Am J ClinPathol 2005; 123: 113-8.

Ingsathit A, Thakkinstian A, Chaiprasert A, Sangthawan P, Gojaseni P, Kiattisunthorn K, et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant 2010; 25: 1567-75.

Chittinandana A, Chailimpamontree W, Chaloeiphap P. Prevalence of chronic kidney disease in Thai adult population. J Med Assoc Thai 2006; 89 (Suppl 2): S112-20.

สุชาติ เจนเกรียงไกร. ความชุกของโรคไตเรื้อรัง ระยะต่างๆในผู้ที่มารับบริการตรวจสุขภาพที่ โรงพยาบาลมหาราชนครราชสีมา. เวชสารโรงพยาบาล มหาราชนครราชสีมา 2551; 32 (ฉบับผนวก 1): S158-64.

Available from http://www.accessdata.fda.gov/psn/transcript.cfm? show=59#2 (Accessed on January 10, 2007)

Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am SocNephrol 2009; 4: 470-80.

Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Jootar S, Intragumtornchai T, Tungsanga K. et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011; 80: 88-92.

Sundal E, Businger J, Kappeler A. Treatment of transfusion-dependent anaemia of chronic renal failure with recombinant human erythropoietin. A European multicentre study in 142 patients to define dose regimen and safety profile.Nephrol Dial Transplant 1991; 6: 955-65.

Power NR, Griffiths RI, Bass EB. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease. J Am SocNephrol 1993; 3: 1660-71

Ifudu O, Macey LJ, Friedman EA. Resurgence of blood transfusion therapy in erythropoietin treated hemodialysis patients. ASAIO J 1995; 41: M426-30.

Duclos J, Olea C, Aguirre H, Alvarez MC, Salgado MC. Erythropoietin and transfusions in patients with anemia of chronicrenal failure.Rev Med Chil 1995; 123: 451-5. [Article in Spanish]

Frankenfield DL, Johnson CA. Current management of anemia in adult hemodialysis patients with end-stage renal disease. Am J Health Syst Pharm 2002; 59: 429-35.

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetinalfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-98.

Berns JS. Should all patients with chronic kidney disease receive an EPO-type drug? Cleveland Clin J Med 2006; 73: 298-300.

Aramwit P, Palapinyo S, Wiwatniwong S, Supasyndh O. The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients.Int J ClinPharmacol Ther 2010; 48: 803-13.

Bamgbola OF. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int 2011; 80: 464-74.

Adamu B,Ma'aji SM, Erwin PJ,Tleyjeh IM. Meta-analysis of randomized controlled trials on androgens versus erythropoietin for anaemia of chronic kidney disease: Implications for developing countries.Int J Nephrol 2012; 2012: 580437. Published online 2012 October 16. doi: 10.1155/2012/580437

Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382: 260-72. doi: 10.1016/S0140-6736(13)60687-X. Epub 2013 May 31.

Weir MR, Fink JC. Salt intake and progression of chronic kidney disease: an overlooked modifiable exposure? A commentary.Am J Kidney Dis 2005; 45: 176-88.

Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Jootar S, Intragumtornchai T, Tungsanga K, et al.

Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011; 80: 88-92. doi: 10.1038/ki.2011. 68. Epub 2011 Mar 23.

Fijal B, Ricci D, Vercammen E, Palmer PA, Fotiou F, Fife D, et al. Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia.

Pharmacogenomics 2008; 9: 157-67. doi: 10.2217/ 14622416.9.2.157.

Brunner FP, Fassbinder W, Broyer M, Oulès R, Brynger H, Rizzoni G, et al. Survival on renal replacement therapy: data from the EDTA Registry. Nephrol Dial Transplant 1988; 3: 109-22.

Lohse N, Hansen ABE, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, et al. Survival of Persons with and without HIV Infection in Denmark, 1995- 2005. Ann Intern Med 2007; 146: 87-95.